1. Dopamine versus norepinephrine as the first-line vasopressor in the treatment of cardiogenic shock.
- Author
-
Na, Soo Jin, Yang, Jeong Hoon, Ko, Ryoung-Eun, Chung, Chi Ryang, Cho, Yang Hyun, Choi, Ki Hong, Kim, Darae, Park, Taek Kyu, Lee, Joo Myung, Song, Young Bin, Choi, Jin-Oh, Hahn, Joo-Yong, Choi, Seung-Hyuk, and Gwon, Hyeon-Cheol
- Subjects
DOPAMINE ,CARDIOGENIC shock ,NORADRENALINE ,SHOCK therapy ,MEDICAL records ,CORONARY care units ,CHONDROITIN sulfates ,FLECAINIDE - Abstract
Background: Only a few observational studies using small patient samples and one subgroup analysis have compared norepinephrine and dopamine for the treatment of cardiogenic shock (CS). The objective of the present study was to investigate whether the use of norepinephrine was associated with improvements in clinical outcomes in CS patients compared to dopamine. Methods: We retrospectively reviewed hospital medical records of patients who were admitted to cardiac intensive care unit from 2012 to 2018. We included 520 patients with CS in this analysis. The primary outcome was in-hospital mortality, and serial hemodynamic data were also assessed. Results: As a first-line vasopressor, dopamine was used in 156 patients (30%) and norepinephrine in 364 patients (70%). Overall, the norepinephrine group had significantly higher severity of shock, arrest at presentation, vital signs, and lactic acid than did the dopamine group at the time of vasopressor initiation. Nevertheless, in the norepinephrine group, additional vasopressor was required in 123 patients (33.8%), which was a significantly smaller percentage than the 92 patients (56.4%) in the dopamine group who required additional vasopressor (p < 0.001). There was no significant difference in in-hospital mortality between the two groups (26.9% and 31.9%, respectively, p = 0.26). In addition, the incidence of arrhythmia was not different between the two groups (atrial fibrillation, 12.2% vs. 15.7%, p = 0.30; ventricular tachyarrhythmia, 19.9% vs. 25.3%, p = 0.18). Conclusions: The use of norepinephrine as a first-line vasopressor was not associated with reductions of in-hospital mortality or arrythmia but could reduce use of additional vasopressors in CS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF